1. Serum levels of inflammation‐related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
   Marianne E. Nome et al, 2020, International Journal of Cancer CrossRef
2. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
   Karine Flem-Karlsen et al, 2020, Molecular Cancer Therapeutics CrossRef
3. AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia
   Mariam Fatima et al, 2021, BMC Cancer CrossRef
4. AXL as a Target in Breast Cancer Therapy
   Sierra A. Colavito, 2020, Journal of Oncology CrossRef
5. Targeting Signaling Pathways in Inflammatory Breast Cancer
   Xiaoping Wang et al, 2020, Cancers CrossRef
6. The Profile of MicroRNA Expression and a Group of Genes in Breast Cancer: Relationship to Tumor Progression and Immunohistochemical Status
   E. A. Filippova et al, 2021, Russian Journal of Genetics CrossRef
7. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
   Italia Falcone et al, 2020, International Journal of Molecular Sciences CrossRef
8. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
   Marie-Anne Goyette et al, 2018, Cell Reports CrossRef
9. A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells
   Jia Z. Shen et al, 2022, Molecular Cell CrossRef
10. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma
    Andrea Ronchi et al, 2021, Seminars in Cancer Biology CrossRef
11. MicroRNA 34a–AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells
    Dansaem Lim et al, 2020, Genes CrossRef
12. MicroRNA-432 Acts as a Prognostic Biomarker and an Inhibitor of Cell Proliferation, Migration, and Invasion in Breast Cancer
    Jianhua Wu et al, 2021, Clinical Breast Cancer CrossRef
13. Axl signaling is an important mediator of tumor angiogenesis
    Mai Tanaka et al, 2019, Oncotarget CrossRef
14. SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
    Chun‐Bong Synn et al, 2022, Clinical & Translational Immunology CrossRef
15. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study
    Thomas Bardol et al, 2024, Cancer Medicine CrossRef
16. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
    Dandan Xu et al, 2021, European Journal of Medicinal Chemistry CrossRef
17. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer
    Rumeysa Ozyurt et al, 2023, Molecular Cancer Therapeutics CrossRef